Context Therapeutics Inc. reports a Schedule 13G disclosure showing 5,250,000 shares of Common Stock beneficially owned, representing 5.7% of the class. The filing is a joint statement by Octagon Capital Advisors LP, Octagon Investments Master Fund LP and Ting Jia. The disclosed position is held with shared voting and shared dispositive power for 5,250,000 shares. The filing notes that Octagon is the investment advisor to the Master Fund and that Dr. Jia is Octagon's controlling member; the Master Fund holds the shares for its investors.
The filing documents a passive Schedule 13G-style disclosure of 5,250,000 shares, with shared voting and dispositive power. It attributes beneficial ownership across Octagon, the Master Fund, and Dr. Jia, reflecting manager/beneficial owner relationships.
Timing and trading intent are not asserted here; subsequent filings could show changes. Cash‑flow treatment and any sale plans are not described in the excerpt.
Joint filing clarifies advisor and control relationships.
The statement explains that Octagon acts as investment advisor to the Master Fund and that Dr. Jia is Octagon's managing member, creating shared voting/dispositive rights over the reported 5,250,000 shares. The Master Fund is identified as the holder for its investors.
Ownership above 5.0% triggers reporting obligations; the filing meets that disclosure requirement. Any beneficiary identities within the Master Fund are not listed in this excerpt.
Key Figures
Shares beneficially owned:5,250,000 sharesPercent of class:5.7%CUSIP:21077P108+1 more
4 metrics
Shares beneficially owned5,250,000 sharesreported amount in Schedule 13G
Percent of class5.7%percent of common stock as reported
CUSIP21077P108security identifier on the filing cover
Filing signatory date05/14/2026signature date on the Schedule 13G
"This statement is being jointly filed by: Octagon Capital Advisors"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared dispositive powerfinancial
"Shared Dispositive Power 5,250,000.00"
Beneficial ownershipfinancial
"Amount beneficially owned: 5,250,000"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Context Therapeutics Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
21077P108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
21077P108
1
Names of Reporting Persons
Octagon Capital Advisors LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,250,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,250,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,250,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.7 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
21077P108
1
Names of Reporting Persons
Octagon Investments Master Fund LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,250,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,250,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,250,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.7 %
12
Type of Reporting Person (See Instructions)
PN, OO
SCHEDULE 13G
CUSIP Number(s):
21077P108
1
Names of Reporting Persons
Ting Jia
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,250,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,250,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,250,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.7 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Context Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA, 19103
Item 2.
(a)
Name of person filing:
This statement is being jointly filed by:
Octagon Capital Advisors LP ("Octagon")
Octagon Investments Master Fund LP ("Master Fund")
Ting Jia, as the principal beneficial owner of Octagon ("Dr. Jia")
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
Octagon serves as the investment manager of the Master Fund. Dr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Dr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065.
(c)
Citizenship:
Octagon is a Delaware limited partnership. The Master Fund is an exempted limited partnership established in the Cayman Islands. Dr. Jia is a Chinese citizen.
(d)
Title of class of securities:
Common Stock, $0.001 par value
(e)
CUSIP Number(s):
21077P108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
5,250,000
(b)
Percent of class:
5.7 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
5,250,000
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
5,250,000
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Octagon is the investment advisor to the Master Fund and other accounts. Dr. Jia is the control person of Octagon. The Master Fund holds the Common Shares for the benefit of its investors. The Master Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Octagon Capital Advisors LP
Signature:
/s/ Ting Jia
Name/Title:
Managing Member
Date:
05/14/2026
Octagon Investments Master Fund LP
Signature:
/s/ Ting Jia
Name/Title:
Managing Member, Octagon Investments GP, LLC, its general partner
What stake in Context Therapeutics (CNTX) does Octagon report?
Octagon reports beneficial ownership of 5,250,000 shares, equal to 5.7% of the Common Stock. The position is disclosed as jointly filed by Octagon, Octagon Investments Master Fund, and Ting Jia with shared voting and dispositive power.
Who holds voting and dispositive power over the reported CNTX shares?
The filing discloses shared voting and shared dispositive power over 5,250,000 shares. Octagon is the investment advisor to the Master Fund and Ting Jia is the managing member of Octagon, per the joint statement.
Does the Schedule 13G say the Master Fund or Octagon will sell shares?
No sale plans are stated in the excerpt. The filing describes beneficial ownership and advisor/controller relationships; it does not specify any intended sales, cash‑flow treatment, or trading arrangements for the 5,250,000 shares.
Why is this Schedule 13G filing joint among multiple parties?
The filing is joint because Octagon manages the Master Fund and Ting Jia controls Octagon. By virtue of these relationships, Octagon and Dr. Jia may be deemed to beneficially own the Master Fund's 5,250,000 shares (5.7%) and therefore filed together.
